Aerie raises $125M in pair of offerings

Ophthalmic play Aerie Pharmaceuticals Inc. (NASDAQ:AERI) raised a combined $125 million in a follow-on and at-the-market offering. Cantor Fitzgerald is managing both. The biotech raised $75 million through the sale of 2.5 million shares at $29.50 in the follow-on, and $50 million through the sale of 1.5 million shares in the ATM offering.

After market hours Wednesday, when its shares closed at $21.13, Aerie reported that its Roclatan netarsudil/latanoprost ( PG324) met the primary endpoint in the Phase III Mercury 1 trial (see BioCentury Extra, Sept. 14). ...